Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.4% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 102,344 shares of the life sciences company’s stock after acquiring an additional 1,446 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.06% of Illumina worth $13,191,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its stake in shares of Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. acquired a new stake in Illumina during the 2nd quarter valued at approximately $34,000. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new stake in shares of Illumina in the second quarter worth $61,000. Finally, Mizuho Securities Co. Ltd. purchased a new position in shares of Illumina during the second quarter worth $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 1.4 %

Shares of ILMN stock opened at $146.00 on Wednesday. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $151.40. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. The stock’s fifty day moving average is $134.96 and its two-hundred day moving average is $121.80. The firm has a market capitalization of $23.26 billion, a P/E ratio of -17.91 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period last year, the firm posted $0.32 earnings per share. The company’s revenue for the quarter was down 5.4% on a year-over-year basis. Research analysts expect that Illumina, Inc. will post 3.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on ILMN. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a report on Thursday, October 17th. Scotiabank reduced their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a research report on Wednesday, August 28th. TD Cowen raised shares of Illumina from a “hold” rating to a “buy” rating and raised their price objective for the stock from $126.00 to $144.00 in a research note on Wednesday, August 14th. Finally, Piper Sandler decreased their target price on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $154.33.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.